Category: Ikke-kategoriseret

Through a Distinguished Innovator grant from Novo Foundation to VAR2 Pharma collaborator, University of Copenhagen, the ofCS antibody program has been awarded 1M euro to finalize the preclinical development of the novel cancer targeting antibodies. The grant was partly awarded to promote public private partnerships and entrepreneurship at University of Copenhagen. .

To support the world-wide urgent need for a vaccine against COVID-19 disease, Var2 Pharmaceuticals and VarCT Diagnostics have made their protein engineering and production pipelines available to a joint vaccine program ongoing at the University of Copenhagen in collaboration with AdaptVac (www.adaptvac.com) and Bavarian Nordic (OMX: BAVA, OTC: BVNRY). Read more: www.healthsciences.ku.dk/newsfaculty-news/2020/03/ucph-researchers-receive-eu-grant-for-vaccine-against-coronavirus www.news.ku.dk/all_news/2020/03/partnership-receives-grants-of-dkk-25m-from-the-carlsberg-foundation-to-fight-corona

VAR2 Pharma’s executive chairman and UBC professor Dr. Mads Daugaard has been awarded a 5-year grant from the CIHR to explore how chondroitin sulfate molecules are regulated during cancer progression. The result of this research project may help inform how best to deploy VAR2 Pharma’s therapeutics in solid tumor indications.

CEO & Professor Ali Salanti is awarded the 2021 ‘Industripris’ from the the Danish Academy of Natural Science. The award is given for years of efforts into enabling public private partnerships and drug development partnerships. Read more: https://danaak.dk/phd-og-industripriser/

VAR2 Pharma’s co-authors have published research in the medical journal Cancers that describes the expression of oncofetal chondroitin sulfate in non-small cell lung cancer. The study shows that oncofetal chondroitin sulfate is a prognostic biomarker and an actionable glycosaminoglycan target in non-small cell lung cancer. Read more:

VAR2 will be represented by its COO, Andreas Linderoth Norlin, at this year’s BIO International Convention taking place in Boston 4th to 7th June. We look forward to a great program and many exciting meetings with old and new partners in the biopharma business. See you there!

VAR2 Pharmaceuticals co-authors have published an article in Nature Communications entitled “Cryo-EM reveals the architecture of placental malaria VAR2CSA and provides molecular insight into chondroitin sulfate binding”. This article reports the high-resolution structure of our proprietary cancer targeting molecule, VAR2CSA, and sheds light on the complex interaction between VAR2CSA and oncofetal chondroitin sulfate in tumors […]

On May 3rd 2019 Co-founder and Chairman of the Board, Dr. Mads Daugaard, was awarded St. Baldrick’s Foundation Awards One-of-a-Kind Grant to Aid in Childhood Cancer Research Discovery for his work to identify and exploit secondary modifications of proteins as targets for novel experimental immunotherapies. We are very proud and happy for this appreciation of Dr. Daugaard’s great personal acheivements. […]

Today the Innovation Fund Denmark (innovationsFonden) granted 1 million DKK over 3 years to VAR2 Pharmaceuticals and Copenhagen University to fund an Industry PhD student in the project “Cancer immunotherapy based on a malaria protein”. We are very happy for the grant and look forward to work with the talented soon-to-be new PhD student Jessica […]

Var2 Pharmaceuticals has been selected as the European winner of the 2020 Advance Biotech Grant Program (SigmaMillipore). VAR2 Pharmaceuticals was chosen for its development of a promising novel pre-clinical cancer drug-conjugate treatment with the potential to treat multiple types of human adult and childhood solid tumors.